Virginia Clark

BIO89-100-132 A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Compensated Cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Prospective Observational Study on the Natural History of Alpha-1 Antitrypsin Deficiency Associated Liver Disease

A Retrospective Natural History Study in Patients Diagnosed with Alpha-1 Antitrypsin Deficiency associated Liver Disease (AATD-LD)

A Phase 3, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Fazirsiran in Participants With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

A Phase 2, Randomized, Double-blind, Placebo-controlled Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Dose Levels of Belcesiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease with METAVIR Stage F2 to F4 Fibrosis

A Phase 2, Open-label Study Evaluating Efficacy and Safety of VX-864 in Subjects With Alpha-1 Antitrypsin Deficiency Who Have the PiZZ Genotype, Over 48 Weeks

A Phase 1, Open-Label Study Evaluating the Liver Tissue Concentration of VX-864 in Subjects Who Have the PiZZ Genotype and Healthy Subjects

The effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects with Biopsy Confirmed NASH

Role of Screening and Early Intervention in Primary Care with Low-Dose Pioglitazone for Patients with T2DM and NASH

Investigation of efficacy and safety of semaglutide s.c. once-weekly versus placebo in subjects with non-alcoholic steatohepatitis and compensated liver cirrhosis

A Placebo-Controlled, Multi-dose, Phase 2/3 Study to Determine the Safety, Tolerability and Effect on Liver Histologic Parameters in Response to ARO-AAT in Patients with Alpha-1 Antitrypsin Deficiency (AATD)

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and fibrosis

TARGET-PBC "A 5-year Longitudinal Observational Study of Patients with Primary Biliary Cholangitis"

Fund 214 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and fibrosis

214 Fund A PHASE 2, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTIPLE CENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF NGM282 ADMINISTERED FOR 12 WEEKS IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS (PSC)

A MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF EMRICASAN (IND-6556) AN ORAL CASPASE INHIBITOR IN..

a 12 week double blind randomized placebo-controlled

LAL-CSS01 A STUDY TO IDENTIFY THE FREQUENCY OF LYSOSOMAL ACID LIPASE DEFICIENCY IN AT-RISK PATIENT POPULATIONS

CLARK PAYROLL OPERATING ACCOUNT

00087226 Clark, V GENFIT GFT505-212-7 'A Study to Evaluate the Efficacy and Safety of GFT505 Once Daily on Steatohepatitis in Patients with (NASH) A Multicentre, Rand DB, Placebo-Controlled Study, with an Adaptive Design